COMMUNIQUÉS West-GlobeNewswire

Nanox to Launch FDA-Cleared Nanox.ARC X and Present development of new AI innovations at RSNA 2025 Annual Meeting
13/11/2025
Live demonstrations of Nanox.ARC X to be featured at RSNA booth ( 3914, South Hall Level 3) every 30 minutes Innovation Theater p resentation to highlight development of pulmonary nodule AI solution, as future component [...]
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
13/11/2025
Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the [...]
La MHRA approuve la demande d’essai clinique de BetaGlue Therapeutics pour YntraDose™ dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
13/11/2025
MILAN, 13 nov. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société d’oncologie en phase clinique développant une solution innovante de radiothérapie pour le traitement ciblé [...]
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
13/11/2025
Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli ™ , the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension COMMACK, NY, [...]
Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers
13/11/2025
Geleen, November 13 th , 2025. Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced top line results from its phase 1 study evaluating the [...]
GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector
13/11/2025
GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector Évry-Courcouronnes , France, N ovemb er 16th , 2025 - GenoSafe, the [...]
GenoSafe étend son leadership en expertise analytique avec l’ouverture de nouveaux laboratoires aux standards internationaux pour soutenir la filière des thérapies innovantes
13/11/2025
GenoSafe étend son leadership en expertise analytique avec l’ouverture de nouveaux laboratoires aux standards internationaux pour soutenir la filière des thérapies innovantes Évry-Courcouronnes , le 13 novembre 2025 - [...]
Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic
13/11/2025
New funding brings total capital raised to $135 million Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their [...]
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
13/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., [...]
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
13/11/2025
Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds to Large Compendium of [...]
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
13/11/2025
Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and [...]
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
13/11/2025
DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
13/11/2025
Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING [...]
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
13/11/2025
Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024 83% Growth in Year-Over-Year Revenue for International Medical Cannabis International Medical sales now 56% of Total Revenue Increased Cash Balance of $ [...]
Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.
13/11/2025
KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. ( CSE: MOOD | PINK: DOSEF | FSE: VU70 ) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is [...]
IMU Biosciences announces formation of Scientific Advisory Board
13/11/2025
PRESS RELEASE Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and genetics London, UK, 13 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company [...]
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
13/11/2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
13/11/2025
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
13/11/2025
New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatment All six patients responded positively to the combination Overall response data [...]

Pages